Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 May;73(9):1148–1151. doi: 10.1038/bjc.1996.220

Blood transfusion as a risk factor for non-Hodgkin lymphoma.

L Brandt 1, J Brandt 1, H Olsson 1, H Anderson 1, T Möller 1
PMCID: PMC2074411  PMID: 8624279

Abstract

In a case-control study of 280 out of 426 consecutive patients with a recent diagnosis of non-Hodgkin lymphoma (NHL) and 1827 control subjects, 53 (19%) and 230 (13%) respectively had received blood transfusions 1 year or more before the interview. Using an age- and sex-stratified analysis the odds ratio (OR) for transfusion was 1.74 (95% CI 1.24-2.44). ORs were also determined for transfusions received in the intervals 1-5, 6-15, 16-25 and > or = 26 years before diagnosis. In the interval 6-15 years, the OR for transfusion was 2.83 (95% CI 1.60-4.99) whereas ORs for transfusions received in other intervals were lower and not significantly elevated. Histological diagnoses (Kiel classification) and results of staging procedures were known for 185 patients. For low-grade NHL of nodal B-cell chronic lymphocytic leukaemia (B-CLL) or immunocytoma type, the OR for transfusions was 4.15 (95% CI 1.92-9.01). For low-grade nodal lymphomas of follicle centre cell type and high-grade nodal lymphomas, no relation to transfusions could be demonstrated. For high-grade extranodal lymphoma as sole manifestation, OR for transfusions was 3.27 (95% CI 1.30-8.24). It is concluded that blood transfusion may be a risk factor for NHLs especially those of B-CLL or immunocytoma type and for high-grade extranodal lymphoma.

Full text

PDF
1149

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beral V., Peterman T., Berkelman R., Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet. 1991 Apr 6;337(8745):805–809. doi: 10.1016/0140-6736(91)92513-2. [DOI] [PubMed] [Google Scholar]
  2. Blomberg J., Möller T., Olsson H., Anderson H., Jonsson M. Cancer morbidity in blood recipients--results of a cohort study. Eur J Cancer. 1993;29A(15):2101–2105. doi: 10.1016/0959-8049(93)90042-e. [DOI] [PubMed] [Google Scholar]
  3. Bordin J. O., Heddle N. M., Blajchman M. A. Biologic effects of leukocytes present in transfused cellular blood products. Blood. 1994 Sep 15;84(6):1703–1721. [PubMed] [Google Scholar]
  4. Carli P. M., Boutron M. C., Maynadié M., Bailly F., Caillot D., Petrella T. Increase in the incidence of non-Hodgkin's lymphomas: evidence for a recent sharp increase in France independent of AIDS. Br J Cancer. 1994 Oct;70(4):713–715. doi: 10.1038/bjc.1994.380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cartwright R., McNally R., Staines A. The increasing incidence of non-Hodgkin's lymphoma (NHL): the possible role of sunlight. Leuk Lymphoma. 1994 Aug;14(5-6):387–394. doi: 10.3109/10428199409049694. [DOI] [PubMed] [Google Scholar]
  6. Cerhan J. R., Wallace R. B., Folsom A. R., Potter J. D., Munger R. G., Prineas R. J. Transfusion history and cancer risk in older women. Ann Intern Med. 1993 Jul 1;119(1):8–15. doi: 10.7326/0003-4819-119-1-199307010-00002. [DOI] [PubMed] [Google Scholar]
  7. Fischer E., Lenhard V., Seifert P., Kluge A., Johannsen R. Blood transfusion-induced suppression of cellular immunity in man. Hum Immunol. 1980 Oct;1(3):187–194. doi: 10.1016/0198-8859(80)90013-0. [DOI] [PubMed] [Google Scholar]
  8. George C. D., Morello P. J. Immunologic effects of blood transfusion upon renal transplantation, tumor operations, and bacterial infections. Am J Surg. 1986 Sep;152(3):329–337. doi: 10.1016/0002-9610(86)90269-2. [DOI] [PubMed] [Google Scholar]
  9. Heiss M. M., Mempel W., Jauch K. W., Delanoff C., Mayer G., Mempel M., Eissner H. J., Schildberg F. W. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet. 1993 Nov 27;342(8883):1328–1333. doi: 10.1016/0140-6736(93)92247-q. [DOI] [PubMed] [Google Scholar]
  10. Memon A., Doll R. A search for unknown blood-borne oncogenic viruses. Int J Cancer. 1994 Aug 1;58(3):366–368. doi: 10.1002/ijc.2910580310. [DOI] [PubMed] [Google Scholar]
  11. Opelz G., Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 1993 Dec 18;342(8886-8887):1514–1516. doi: 10.1016/s0140-6736(05)80084-4. [DOI] [PubMed] [Google Scholar]
  12. Stansfeld A. G., Diebold J., Noel H., Kapanci Y., Rilke F., Kelényi G., Sundstrom C., Lennert K., van Unnik J. A., Mioduszewska O. Updated Kiel classification for lymphomas. Lancet. 1988 Feb 6;1(8580):292–293. doi: 10.1016/s0140-6736(88)90367-4. [DOI] [PubMed] [Google Scholar]
  13. Starzl T. E., Nalesnik M. A., Porter K. A., Ho M., Iwatsuki S., Griffith B. P., Rosenthal J. T., Hakala T. R., Shaw B. W., Jr, Hardesty R. L. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984 Mar 17;1(8377):583–587. doi: 10.1016/s0140-6736(84)90994-2. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES